Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland
Latest Information Update: 19 Jun 2024
Price :
$35 *
At a glance
- Drugs Venetoclax (Primary) ; Obinutuzumab; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms Verve
- Sponsors AbbVie
- 12 Dec 2023 Results (n=28) assessing Multilayer Profiling of MRD in Patients with Relapsed/Refractory CLL Treated with Venetoclax-Based Regimens presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing effectiveness and safety data were analyzed for therapy naive patients treated with VenO focusing on CLL patients with or without the genetic risk factors TP53 mut and/or del(17p) as well as IGHV status, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 15 Jun 2023 Results of Comparison of Patients in Line or Out of Scope with Cll14 and analyzing safety and effectiveness, presented at the 28th Congress of the European Haematology Association